|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's Range||24.20 - 24.20|
|52 Week Range||8.80 - 56.50|
|Beta (5Y Monthly)||0.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -10.14% and -29.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent progress and upcoming milestones for its pipeline programs.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...